Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Ilaria Muller, PhD student, Cardiff University, on a possible common antigen between thyroid cancer and breast cancer. Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Muller sadds that in most forms of thyroid cancer, the thyroid can be removed and replacement treatments for its function can be taken. Muller and colleagues at Cardiff Univeristy are currently investigating the topic of thyroid autoimmunity as a biomarker of outcome in women with breast cancer by way of a large-scale study using data from the Taxotere As Adjuvant Chemotherapy (Tact) Trial (Cruk01/001).
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More